Surface Oncology, Inc. SURF · Stock Open Surface Oncology, Inc. in new tab
Surface Oncology, Inc. Analysis (SURF)
Is Surface Oncology, Inc. a good investment? Surface Oncology, Inc. (SURF) is currently trading at 1.07 USD.
Investor FAQ
Does Surface Oncology, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Surface Oncology, Inc.?
Surface Oncology, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
Company Profile
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Community Discussion